Why Average Weight Change Is Not Your Predicted Result

A weight-loss percentage can look like a personal forecast when it appears beside an enrollment button. But a study average answers a narrower question: what happened, on average, to a defined group receiving a particular intervention over a specified period? It does not tell you what will happen after you complete an online questionnaire, receive a prescription or join a provider’s program. The difference matters before you turn a published percentage into a goal, a deadline or a reason to pay.

This guide separates three evidence questions: what randomized trials established, what providers document about their services, and what remains for a treating clinician to evaluate. Examples come from CoreAge Rx, Ro, Enhance.MD, Sesame, Walgreens and Found public documentation consulted October 19, 2026. Those pages describe real differences in evaluation and follow-up, but they are not interchangeable with research on individual outcomes. No personalized prediction range can be responsibly created from the evidence reviewed here.

At a glance

An average is not a forecast: STEP 1 and SURMOUNT-1 report group outcomes for specific study populations and interventions, not predicted results for an individual or reviewed provider.
Sources: [3] [4]
Study conditions matter: STEP 1 studied subcutaneous semaglutide over 68 weeks; SURMOUNT-1 studied subcutaneous tirzepatide over 72 weeks. Both populations excluded diabetes.
Sources: [3] [4]
Clinical evaluation remains necessary: NIDDK identifies benefits, side effects, health conditions, other medicines, family history and costs as factors in medication selection.
Sources: [2]
Compounded products require a separate assessment: Compounded preparations are not FDA approved. FDA recommends them when an individual’s medical needs cannot be met by an approved drug.
Sources: [1]
Service descriptions are not outcome studies: Ro documents check-ins and messaging, while Found describes monthly follow-up for compounded tirzepatide. These statements describe services, not verified weight-loss results.
Sources: [20] [5]

Start with the question the percentage actually answers

An average summarizes a group; it does not assign that same result to each participant. Knowing a trial’s mean weight change does not reveal your likely outcome, your timing or the amount of uncertainty around a personal estimate. The evidence reviewed here supplies no validated individual prediction tool. Adding an invented “typical range” would not solve that problem—it would replace a documented group statistic with an unsupported personal-looking forecast.

Before using a number, identify its population, intervention, comparator and endpoint. Then ask whether the claim concerns an actual medication study or merely appears on a company’s marketing page. Our guide to clinical trials versus company performance reports develops that distinction. A provider may accurately reference research without having measured comparable outcomes among its own patients. Citation accuracy and applicability are separate questions, and both deserve attention.

Five checks before treating a weight-change claim as relevant to you
Check	What to identify	What it cannot establish alone
Population	Who entered the study and who was excluded	Your individual eligibility or result
Intervention	Product, formulation, route and studied dose	Results for another preparation
Time	The endpoint used for the reported average	Your progress at an earlier date
Comparator	What the treatment group was compared with	A ranking against an untested competitor
Tolerability	Adverse effects and treatment discontinuation	Your personal experience of treatment

Sources: [3] [4]

Read STEP 1 as a trial, not a promise

STEP 1 was a double-blind randomized trial involving 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes. Over 68 weeks, mean weight change was −14.9% in the group studying subcutaneous semaglutide 2.4 mg weekly and −2.4% with placebo. Both groups received lifestyle intervention. The dose identifies the research arm only; it is not an instruction for readers. Novo Nordisk funded the trial.

Tolerability belongs beside the headline result: gastrointestinal events led to discontinuation in 4.5% of the semaglutide group and 0.8% of the placebo group. Neither the average nor that discontinuation percentage predicts one person’s experience. These were not measured outcomes for CoreAge Rx, Found or another reviewed clinic. They also do not establish results for compounded semaglutide, oral preparations, microdoses or vitamin blends. See our STEP 1 reading guide for a focused explanation.

Sources: [3]

Keep SURMOUNT-1 in its own frame

SURMOUNT-1 was a double-blind randomized trial of 2,539 adults with obesity, or overweight plus a weight-related complication, excluding diabetes. At 72 weeks, mean weight changes were −15.0%, −19.5% and −20.9% in the studied subcutaneous tirzepatide 5, 10 and 15 mg weekly groups, respectively, versus −3.1% with placebo. These doses identify study groups, not recommended treatment choices. Eli Lilly funded the trial.

Gastrointestinal events were the most common adverse events. Discontinuation because of adverse events occurred in 4.3%, 7.1% and 6.2% of the respective tirzepatide groups, compared with 2.6% for placebo. Comparing these averages directly with STEP 1 does not create a randomized head-to-head comparison. Nor does either study establish which telehealth platform delivers better results. Our SURMOUNT-1 interpretation guide explains why a higher-looking percentage is not a provider ranking.

Sources: [4]

Match the evidence to the actual preparation

Product descriptions can differ substantially even when familiar ingredient names appear. CoreAge Rx says its compounded tirzepatide is typically formulated with B-12; an alternative without B-12 can be discussed during intake. It separately markets semaglutide and tirzepatide microdosing therapies. Enhance.MD markets Core as injectable semaglutide, Advanced as compounded tirzepatide and Elite as an injectable combination of semaglutide and tirzepatide. These are documented offerings, not evidence that the trial averages apply to each preparation.

FDA approval belongs to a specific product, not a clinic or pharmacy. Compounded preparations are not FDA approved and do not undergo FDA premarket review for safety, effectiveness and quality. That alone proves neither clinical equivalence nor inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our guide to approved and compounded evidence questions explains why ingredient recognition is only the beginning.

Sources: [11] [12] [13] [7] [17] [22] [1]

Use intake to investigate fit, not confirm a forecast

Provider questionnaires are gateways to evaluation, not substitutes for it. Ro asks about medical history, lifestyle and goals; a provider determines eligibility and may request a metabolic lab test. Sesame describes a video consultation about history and goals, with laboratory testing if metabolic data is needed. Walgreens describes a health questionnaire followed, if qualified, by an on-demand video visit. Each process leaves a clinical decision between interest in a medication and an actual prescription.

Enhance.MD’s documentation describes identity verification, baseline testing through Quest Diagnostics and an email to schedule a video consultation after results arrive. Its stated minimum BMI is 25 for new patients and 20 for maintenance patients currently taking or recently having taken GLP-1 treatment, with medical history also considered. These are provider-specific criteria, not universal rules. NIDDK’s broader framework includes current conditions, other medicines, family history, benefits, adverse effects and costs—information a study average cannot evaluate for you.

Sources: [14] [21] [16] [10] [6] [2]

Ask what follow-up means when your response is uncertain

A useful follow-up question is not simply whether messaging exists, but how the service evaluates response and tolerability. Ro advertises unlimited provider messaging, side-effect management, tracking tools and individual coaching. Found says its care team follows up monthly for compounded tirzepatide and offers messaging between visits for semaglutide. Walgreens says most follow-up visits occur through chat, with another on-demand video visit available when real-time support is needed. These describe different contact structures, not comparative clinical effectiveness.

CoreAge Rx says plans include ongoing provider access, but the reviewed documentation does not establish a consultation frequency or continuing clinical response deadline. Its “24/7 Provider Support” heading is followed by text about customer support, not continuous prescriber availability. Enhance.MD offers a portal for reviewing treatment and laboratory results and contacting the care team. NIDDK emphasizes that follow-up concerns tolerance and response; access to a portal or renewal payment alone does not document that clinical work.

Sources: [20] [5] [15] [16] [18] [10] [2]

Separate testimonials and quality claims from outcome evidence

Ro discloses that members were paid for testimonials. That disclosure is useful, but the testimonials are not verified clinical outcome data. Found says its compounded semaglutide undergoes third-party testing for potency, purity and sterility before shipment. Those are provider statements about product testing; the reviewed documentation does not identify the external laboratory or provide certificates of analysis. Even documented quality testing would answer a different question from how much weight a particular person will lose.

The same distinction applies to access claims. Found says most members can start treatment within a week, while CoreAge Rx estimates approximately 24 hours for initial medical feedback and notes that some states require video or live chat. Neither statement measures treatment effectiveness. Nor does a rapid review establish rapid delivery or an individual outcome. Keep operational claims in an operational category rather than allowing convenience language to become implied evidence of superior results.

Sources: [20] [15] [9] [11] [3] [4]

Prepare for a decision without inventing a personal range

Bring the clinician questions that a published average leaves unanswered: Which exact product is being considered? What evidence applies to that formulation and route? How will response and side effects be reviewed? Who handles questions between visits? NIDDK also advises discussing medicines, supplements, allergies and pregnancy plans. Medication selection is a clinical conversation, not a calculation that multiplies your starting weight by a trial percentage. No individual dosing or adjustment decision follows from this guide.

Practical safety questions remain separate from weight-change expectations. FDA has received reports of compounded-medication measurement or administration errors, some associated with hospitalization; clarify instructions with the prescriber or pharmacist rather than calculating doses from an article. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. Also ask about continuing care: NIDDK notes that treatment duration depends on response and side effects, and obesity may require long-term care.

Sources: [2] [1]

Questions & answers

Does CoreAge Rx’s B-12 formulation inherit the tirzepatide trial results?

No provider-specific result is established here. CoreAge Rx says its compounded tirzepatide typically includes B-12, while SURMOUNT-1 studied specified subcutaneous tirzepatide arms. Ask the clinician what evidence supports the exact preparation offered. The trial average does not become a forecast for that blend or for you.

Sources: [11] [4]

Does Ro’s regular support make its patients’ results predictable?

Ro documents check-ins, messaging and coaching, but those service features do not establish a predictable personal outcome. Ask how your clinician will evaluate response and tolerability and when reassessment occurs. The reviewed pages do not establish a numerical response deadline for messages or a provider-specific outcome forecast.

Sources: [20] [2]

Can Enhance.MD Elite be assumed to outperform single-ingredient options?

Not from these sources. Enhance.MD markets Elite as an injectable semaglutide-and-tirzepatide combination, but neither STEP 1 nor SURMOUNT-1 studied that provider’s combination. Their separate averages cannot be added or repurposed to demonstrate superiority. Ask for evidence specific to the formulation rather than relying on its commercial positioning.

Sources: [22] [3] [4]

Does Sesame’s questionnaire provide a validated personal forecast?

Sesame invites users to complete a questionnaire to see how much weight they could lose and personalize care. The reviewed documentation does not establish that output as a validated prediction. Its clinical process also includes a video consultation, possible laboratory testing and prescribing at the provider’s discretion—not a guaranteed prescription.

Sources: [21] [8]

Is Walgreens’ pharmacy chat the same as clinical follow-up?

No. Walgreens describes 24/7 pharmacy-expert chat separately from Weight Management clinician visits. The pharmacy chat may involve a wait, is not for emergencies and does not replace physician advice. Weight Management follow-up chat visits and additional video visits are advertised at $49 each; pharmacy-chat availability does not establish a zero fee.

Sources: [19] [16]

Does Found’s third-party testing prove clinical equivalence?

Found’s stated testing of compounded semaglutide concerns potency, purity and sterility. It is not a provider-specific clinical outcome study or proof of equivalence to an approved product. Conversely, compounded nonapproval alone does not prove inequivalence. Ask which pharmacy supplies the preparation and what product-specific documentation is available.

Sources: [15] [1]

Our assessment

Study averages are useful evidence when their population, intervention, duration, comparator and tolerability remain attached. They become misleading when treated as your promised result or a score for a telehealth company. The reviewed providers document meaningful differences in intake, formulations and follow-up, but those differences do not establish comparative effectiveness. Use the research to frame a clinician conversation, then evaluate the exact product and care process offered. The responsible conclusion is neither that outcomes are unknowable nor that an average predicts yours: the evidence informs a decision while leaving individual response uncertain.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Why Average Weight Change Is Not Your Predicted Result

At a glance

01Start with the question the percentage actually answers

02Read STEP 1 as a trial, not a promise

03Keep SURMOUNT-1 in its own frame

04Match the evidence to the actual preparation

05Use intake to investigate fit, not confirm a forecast

06Ask what follow-up means when your response is uncertain

07Separate testimonials and quality claims from outcome evidence

08Prepare for a decision without inventing a personal range